Seres Therapeutics Inc
NASDAQ:MCRB
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.5497
  • TODAY'S CHANGE (%)
    -0.0424 (-7.1610%)
  • Bid / Lots
    0.5621/ 20
  • Ask / Lots
    0.5650/ 1,909
  • Open / Previous Close
    0.6044 / 0.5921
  • Day Range
    0.5495
    0.6044
  • 52 Week Range
    0.5400
    2.0500
  • Volume
    3,481,831

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
MCRB
Seres Therapeutics Inc
100.8M
-0.5x
---
HRTX
Heron Therapeutics Inc
188.1M
-6.5x
---
KPTI
Karyopharm Therapeutics Inc
104.9M
-1.0x
---
SPRO
Spero Therapeutics Inc
67.6M
3.7x
---
CTMX
CytomX Therapeutics Inc
78.3M
5.4x
---
FGEN
FibroGen Inc
37.1M
-0.3x
---
As of 2024-11-15

Company Information

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The Company is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The Company's clinical and nonclinical data across its programs support the development of live biotherapeutics to target the prevention and treatment of a broad swath of infections, and in inflammatory and immune diseases.

Contact Information

Headquarters
101 Cambridge Park DriveCAMBRIDGE, MA, United States 02140
Phone
617-945-9626
Fax
302-655-5049

Executives

Independent Chairman of the Board
Stephen Berenson
President, Chief Executive Officer, Director
Eric Shaff
Chief Financial Officer, Executive Vice President
Marella Thorell
Executive Vice President, Chief Technology Officer
David Ege
Executive Vice President, Chief Scientific Officer
Matthew Henn

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$100.8M
Revenue (TTM)
$374.0K
Shares Outstanding
170.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.97
EPS
$-1.18
Book Value
$-0.33
P/E Ratio
-0.5x
Price/Sales (TTM)
269.5
Price/Cash Flow (TTM)
---
Operating Margin
-42,211.23%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.